Morning Immunotherapy Does Not Boost Lung Cancer Survival

Published Date: 01 Apr 2026

Some studies have suggested that morning is the optimal time for immunotherapy, but a new analysis of patients with lung cancer begs to differ.

Read Full News

Latest News

Subcutaneous Toripalimab Matches IV Formulation in NSCLC

Patients with non-squamous non-small cell cancer may achieve similar outcomes with a subcutaneous formulation of the immunotherapy toripalimab as with IV administration.

Can MRI Curb Chemo Overtreatment in Breast Cancer?

MRI offers the possibility of personalized neoadjuvant chemotherapy for patients with HER2-positive breast cancer, but it may not be ready for prime time.

CAR T-Cell Therapy Shows Promise in Mantle Cell Lymphoma

A phase 2 study evaluates the safety and efficacy of brexucabtagene autoleucel in BTKi-naïve patients with relapsed/refractory mantle cell lymphoma.

New Gene Therapy Nears EU Nod for Bladder Cancer

Conditional approval of intravesical gene therapy was supported by clinical evidence showing a 53.4% complete response rate in patients with treatment-resistant non-muscle-invasive bladder cancer.

Biocomputer From Human Neurons Plays Doom, Raises Ethics

A biological computer using human neurons learns Doom within 1 week, highlighting rapid adaptive learning and potential advantages over traditional AI systems.

Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC

The findings could fill a treatment gap for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who also carry TP53 mutations.

Todays Updates

Skipping Lymph Node Biopsy Gains Ground in Breast Cancer

New data show growing adoption of guidance to skip sentinel lymph node biopsy in older women with early breast cancer, though uptake remains slow and incomplete in the US.

Todays Updates

Skipping Lymph Node Biopsy Gains Ground in Breast Cancer

New data show growing adoption of guidance to skip sentinel lymph node biopsy in older women with early breast cancer, though uptake remains slow and incomplete in the US.

Latest News

Patients with non-squamous non-small cell cancer may achieve similar outcomes with a subcutaneous formulation of the immunotherapy toripalimab as with IV administration.

MRI offers the possibility of personalized neoadjuvant chemotherapy for patients with HER2-positive breast cancer, but it may not be ready for prime time.

A phase 2 study evaluates the safety and efficacy of brexucabtagene autoleucel in BTKi-naïve patients with relapsed/refractory mantle cell lymphoma.

Conditional approval of intravesical gene therapy was supported by clinical evidence showing a 53.4% complete response rate in patients with treatment-resistant non-muscle-invasive bladder cancer.

A biological computer using human neurons learns Doom within 1 week, highlighting rapid adaptive learning and potential advantages over traditional AI systems.

The findings could fill a treatment gap for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who also carry TP53 mutations.

News All Time

MRI-Guided TULSA Speeds Recovery vs Robotic Prostatectomy

The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy in men with intermediate-risk prostate cancer.

New Nanoparticles Can Destroy Undruggable Cancer Proteins

Researchers have created nanoparticles that can remove disease-driving proteins while also delivering a chemotherapeutic or immunotherapeutic payload to cancer cells.

Shorter but More Intense RT: A Better Option for HNSCC?

A new analysis explores whether accelerating RT delivery with 6 fractions vs 5 fractions per week improves outcomes in patients with locally advanced HNSCC receiving concurrent chemotherapy.

Adjuvant Tx May Boost Survival in Bilateral Breast Cancer

A population-based cohort study finds that an increased use of adjuvant systemic therapy can improve survival in patients with metachronous and synchronous bilateral breast cancer.

Chemoimmunotherapy Boosts Head and Neck Cancer Response

Neoadjuvant chemoimmunotherapy may beat immunotherapy alone when it comes to pathologic response, but its impact on survival remains to be seen.

Have the Harms of Lung Cancer Screening Been Exaggerated?

Three medical societies claim recent studies have overestimated the potential harms from lung cancer screening and may be deterring patients. Not everyone agrees.

Pretreatment Liver Tests Often Overlooked in CDK4/6 Therapy

Despite FDA package insert recommendations, most patients with breast cancer who are prescribed CDK4/6 inhibitors do not receive liver function tests before starting treatment.

Alternative Medicine for Breast Cancer: Study Raises Concern

Patients who receive both standard medical treatment and complementary and alternative therapies have higher mortality — possibly due to reduced use of endocrine therapy and radiation.

Biomarker Flags 10-Fold Recurrence Risk in Testicular Cancer

MiR-371 isn’t ready for the clinic yet, but it is ready for interventional trials to see if it can refine adjuvant chemotherapy decisions in stage I testicular cancer.

FDA Approves New Drug Combo for RR Multiple Myeloma

Teclistamab plus daratumumab and hyaluronidase-fihj is approved for relapsed or refractory MM after one prior line of therapy, including a proteasome inhibitor and immunomodulatory agent.

Adjuvant Belzutifan Combo Is ‘Practice Changing’ in RCC

Adding belzutifan to standard adjuvant pembrolizumab cut the risk for recurrence or death in patients with resected clear cell renal cell carcinoma.

Immunotherapy Remains Little Used in Head and Neck Cancer

Immune checkpoint inhibitors have been FDA-approved for head and neck cancer for a decade, but their use has only marginally increased among patients younger than 65.

EVP Beats Cisplatin for Resectable MIBC

As the first chemotherapy-free regimen to beat gemcitabine/cisplatin, perioperative enfortumab vedotin plus pembrolizumab could shift muscle-invasive bladder cancer care — but questions remain.

Belzutifan Combo Could be Second-Line Option in Advanced RCC

Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.

Conditional EU Nod for Weekly Pill in Pediatric Glioma

Current treatment options include surgery and chemotherapy, but chemotherapy’s benefits are often modest and can cause substantial side effects.

SBRT May Beat Brachytherapy in Prostate Cancer

In the long term, stereotactic body radiotherapy carries a lower risk for biochemical failure vs high-dose rate brachytherapy for men with intermediate-risk prostate cancer.

Recommended News For You

WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research

PET-CT is better than contrast-enhanced CT as a predictor of survival in patients with metastatic breast cancer

CDC Alerts on Dramatic Rise in Human Parvovirus B19

Breast cancer surgery: Study finds overnight hospital stay not important for older patients

Guidelines for patient training and radiation protection for patients treated with radioactive iodine for thyroid cancer

Artificial intelligence is assisting in the earlier detection and treatment of breast cancer.

Lower screening age calls for more tailored bowel cancer surveillance

Recommended Articles For You

Tumor Evolution: Signaling, Plasticity, and Intratumor Heterogeneity in Cancer 

The Immune Revolution: Neoantigen Vaccines and the Dawn of Personalized Cancer Therapy in 2025 

Decoding Hamartomas: Understanding Their Causes and Symptoms 

PARP Inhibitors in Testicular Cancer: Tackling Cisplatin Resistance with Precision 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The White House has postponed its plan to outlaw menthol cigarettes indefinitely.

2.

Study finds primary-care doctors often overlook prostate cancer risk in Black men

3.

The diamonds that could find cancer

4.

FDA OKs Subcutaneous Daratumumab Plus VRd for Myeloma

5.

A Texas study found that the majority of pancreatic cancer patients do not receive life-saving surgery.

1.

Machine Learning in Genomic Analysis for Early Lung Cancer Detection: Key Advances and Insights

2.

Modern Oncology Unveiled with Treatment Innovations and Personalized Cancer Care

3.

The Statistical Evolution of Cancer Staging and Its Precision Impact on Prognosis and Therapy in Cancer Staging 2025

4.

The latest research on Thyroid Cancer: Symptoms, Diagnosis, and Treatment Options 

5.

The Growing Crisis of Aplastic Anemia: A Call for Action

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients

2.

Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men

3.

Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion

4.

An In-Depth Look At The Signs And Symptoms Of Lymphoma

5.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot